Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Whole brain radiotherapy plus apatinib for EGFR wild-type non-squamous NSCLC with multiple brain metastases
ChiCTR1800015196Phase 4Not yet recruiting
- Sponsor
- Yunnan Cancer Hospital
- Start
- Jan 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by Yunnan Cancer Hospital. Primary endpoint: Intracranial progression-free survival. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on ChiCTR1800015196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015196.